MA38688B1 - Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d - Google Patents

Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Info

Publication number
MA38688B1
MA38688B1 MA38688A MA38688A MA38688B1 MA 38688 B1 MA38688 B1 MA 38688B1 MA 38688 A MA38688 A MA 38688A MA 38688 A MA38688 A MA 38688A MA 38688 B1 MA38688 B1 MA 38688B1
Authority
MA
Morocco
Prior art keywords
oral administration
vitamin
pharmaceutically acceptable
acceptable salt
ibandronic acid
Prior art date
Application number
MA38688A
Other languages
English (en)
Other versions
MA38688A1 (fr
Inventor
Serra João Pedro Silva
Isabel Maria Soares
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38688(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA38688A1 publication Critical patent/MA38688A1/fr
Publication of MA38688B1 publication Critical patent/MA38688B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique solide améliorée pour l'administration orale comprenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci, de la vitamine d et des triglycérides à chaîne moyenne ou des huiles totalement ou partiellement hydrogénées qui confère les propriétés physico-chimiques souhaitables à une formulation solide pour l'administration orale adaptée au traitement de maladies osseuses et de troubles du métabolisme du calcium.
MA38688A 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d MA38688B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
PCT/PT2014/000036 WO2014193255A1 (fr) 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Publications (2)

Publication Number Publication Date
MA38688A1 MA38688A1 (fr) 2017-07-31
MA38688B1 true MA38688B1 (fr) 2018-08-31

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38688A MA38688B1 (fr) 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Country Status (16)

Country Link
US (1) US20160106766A1 (fr)
EP (1) EP3003383B1 (fr)
BR (1) BR112015029897A2 (fr)
CL (1) CL2015003468A1 (fr)
DK (1) DK3003383T3 (fr)
ES (1) ES2705074T3 (fr)
HU (1) HUE040666T2 (fr)
LT (1) LT3003383T (fr)
MA (1) MA38688B1 (fr)
MX (1) MX364680B (fr)
PL (1) PL3003383T3 (fr)
PT (2) PT106978A (fr)
RS (1) RS58133B1 (fr)
SI (1) SI3003383T1 (fr)
TR (1) TR201821157T4 (fr)
WO (1) WO2014193255A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
CA2683628C (fr) 2007-04-25 2018-03-06 Cytochroma Inc. Procede de traitement d'une insuffisance et d'une carence en vitamine d
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
EP1972341A1 (fr) 2007-03-23 2008-09-24 Novartis AG Compositions pharmaceutiques contenant un bisphosphonate et de la vitamine D
WO2010075537A1 (fr) * 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Formule comprenant de la vitamine d ou ses dérivés
EP2416756A2 (fr) * 2009-04-10 2012-02-15 Mahmut Bilgic Compositions pharmaceutiques stables à forte biodisponibilité
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
DK2680826T3 (en) * 2011-03-02 2017-10-09 D3 Pharma Ltd VITAMIN D COMPOSITION

Also Published As

Publication number Publication date
US20160106766A1 (en) 2016-04-21
SI3003383T1 (sl) 2019-03-29
EP3003383B1 (fr) 2018-10-03
PT106978A (pt) 2014-12-02
MA38688A1 (fr) 2017-07-31
RS58133B1 (sr) 2019-02-28
TR201821157T4 (tr) 2019-02-21
PT3003383T (pt) 2019-01-16
CL2015003468A1 (es) 2016-07-22
MX364680B (es) 2019-05-03
ES2705074T3 (es) 2019-03-21
PL3003383T3 (pl) 2019-04-30
EP3003383A1 (fr) 2016-04-13
HUE040666T2 (hu) 2019-08-28
BR112015029897A2 (pt) 2017-07-25
DK3003383T3 (en) 2019-01-28
MX2015016497A (es) 2016-09-08
WO2014193255A1 (fr) 2014-12-04
LT3003383T (lt) 2019-03-12

Similar Documents

Publication Publication Date Title
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA43116B1 (fr) Ditosylate de valbénazine et polymorphes associés
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA34474B1 (fr) Agonistes de gpr40
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA30041B1 (fr) Immunoglobulines
MA35728B1 (fr) Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
FI3177281T3 (fi) Rasvahappojen ja palmitoyylietanoliamidin seos käytettäväksi tulehduksellisten ja allergisten patologioiden hoitoon
EP3539550A4 (fr) Composition pharmaceutique pour la prevention ou le traitement de maladies neurodegeneratives comprenant comme principe actif de l'extrait de fleur de daphné lilas ou des fractions de celui-ci
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
SI1343529T1 (sl) NSAID formulacije, ki vsebujejo lecitinska olja, za zaščito gastrointestinalnega trakta in zagotovitev povečanja terapevtske aktivnosti
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical